Atossa Therapeutics, Inc. (ATOS) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+88.9%

$4.35

vs $2.30 price

Levered DCF

$4.80

After debt service

Piotroski score

1 / 9

Weak

Altman Z-score

-11.86

Distress zone

Rating

B-

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-2.19×	-4.72×	-3.67×	-2.52×	-8.89×	-0.48×	-0.77×	-0.19×
P/B	1.94×	1.66×	1.22×	0.57×	1.35×	0.4×	1.01×	0.48×
P/S	0×	0×	0×	0×	0×	0×	0×	0×
EV / EBITDA	-1×	-1.87×	-0.75×	1.62×	-2.47×	1.99×	-0.04×	0.54×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	5.53×	14.99×	17.61×	21.23×	45.18×	2.73×	10.83×	3.96×
Debt / equity	0×	0×	0×	0×	0×	0×	0×	0×
Interest coverage	0×	0×	0×	0×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-88.4%	-35.7%	-33.1%	-22.9%	-14.9%	-65.6%	-131.0%	-129.5%
Return on invested capital	-94.4%	-38.6%	-34.5%	-23.5%	-14.9%	-53.7%	-130.6%	-129.5%
Return on assets	-73.0%	-33.4%	-31.3%	-21.8%	-14.6%	-41.6%	-118.9%	-97.3%
Free cash flow yield	-39.1%	-17.7%	-18.9%	-31.0%	-8.8%	-107.8%	-68.5%	-213.9%
Earnings yield	-45.6%	-21.5%	-27.1%	-40.2%	-11.0%	-165.9%	-129.2%	-268.9%
Enterprise value	$34.9M	$47.7M	$22.5M	-$43.8M	$50.7M	-$28.9M	$699.6K	-$6.1M
Net debt / EBITDA	1.19×	2.79×	2.94×	4.11×	6.63×	2.72×	0.73×	0.91×
Cash conversion cycle (days)	0	-14,579	10,807	104,116	-27,248	-12,443	-2,027	-2,918